Despite being allowed to select study arms to enhance compliance and to avoid the loss of children, at baseline, none of the parameters assessed differed between the overweight children with NAFLD selecting the intervention arm and those who chose to participate in the feasibility study as controls, with the exception of TNFα levels in plasma (see Figure 4). The gene discussed is TNF; the disease is metabolic dysfunction-associated steatotic liver disease.